The price of Alphatec Holdings Inc (NASDAQ:ATEC) shares last traded on Wall Street fell -2.57% to $9.84.
Based on available information, 10 analysts follow Alphatec Holdings Inc (NASDAQ:ATEC). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $32.00 and a low of $19.00, we find $22.25. Given the previous closing price of $10.10, this indicates a potential upside of 120.3 percent. ATEC stock price is now -26.15% away from the 50-day moving average and -33.93% away from the 200-day moving average. The market capitalization of the company currently stands at $1.18B.
Among analysts, 0 rate the stock a hold while 10 rate it a buy. Brokers who have rated the stock have averaged $23.05 as their price target over the next twelve months.
With the price target of $22, ROTH MKM recently initiated with Buy rating for Alphatec Holdings Inc (NASDAQ: ATEC).
In other news, Miles Patrick, CEO sold 59,375 shares of the company’s stock on Sep 27. The stock was sold for $771,875 at an average price of $13.00. Upon completion of the transaction, the CEO now directly owns 5,452,736 shares in the company, valued at $53.65 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 26, CEO Miles Patrick sold 60,000 shares of the business’s stock. A total of $747,600 was realized by selling the stock at an average price of $12.46. This leaves the insider owning 5,512,111 shares of the company worth $54.24 million. Insiders disposed of 5,693,137 shares of company stock worth roughly $56.02 million over the past 1 year. A total of 37.37% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ATEC stock. A new stake in Alphatec Holdings Inc shares was purchased by AMERICAN CENTURY COMPANIES INC during the first quarter worth $20,979,000. FRED ALGER MANAGEMENT, LLC invested $15,443,000 in shares of ATEC during the first quarter. In the first quarter, PARKWOOD LLC acquired a new stake in Alphatec Holdings Inc valued at approximately $11,808,000. ALYESKA INVESTMENT GROUP, L.P. acquired a new stake in ATEC for approximately $8,027,000. AVIDITY PARTNERS MANAGEMENT LP purchased a new stake in ATEC valued at around $3,867,000 in the second quarter. In total, there are 260 active investors with 57.12% ownership of the company’s stock.
A candlestick chart of Alphatec Holdings Inc (NASDAQ: ATEC) showed a price of $10.08 on Thursday morning. During the past 12 months, Alphatec Holdings Inc has had a low of $8.83 and a high of $19.14. The fifty day moving average price for ATEC is $13.23 and a two-hundred day moving average price translates $14.88 for the stock.
The latest earnings results from Alphatec Holdings Inc (NASDAQ: ATEC) was released for Jun, 2023. According to the Medical Devices Company, earnings per share came in at -$0.43, missing analysts’ expectations of -$0.28 by -0.15. This compares to -$0.36 EPS in the same period last year. The net profit margin was -39.57% and return on equity was -1127.95% for ATEC. The company reported revenue of $116.92 million for the quarter, compared to $84.15 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 38.94 percent. For the current quarter, analysts expect ATEC to generate $113.39M in revenue.
Alphatec Holdings Inc(ATEC) Company Profile
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. It manufactures and sells implants and instruments through third-party suppliers. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform; Sigma PTP Access and Patient Positioning System; split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; EOS imaging system that provides full-body imaging; spinal implants and fixation systems; and NanoTec and Calibrate PSX, as well as various standalone implants for height restoration and stabilization. It also provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix, a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM; AlphaGRAFT Demineralized Bone Matrix comprising demineralized human tissues; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives in the United States and internationally. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
